Results 231 to 240 of about 239,330 (291)

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul   +13 more
wiley   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao   +27 more
wiley   +1 more source

In Vivo Evaluation of a Nanoemulsion-Delivered Chromium(III)-Triazole Complex Against Fluconazole-Resistant <i>Candida albicans</i>. [PDF]

open access: yesJ Fungi (Basel)
Bedoya-Florez MV   +7 more
europepmc   +1 more source

The Influence of Sex, Ear, and Age on Auditory Brainstem Responses Recorded with the NeuroAudio System. [PDF]

open access: yesDiagnostics (Basel)
Sanfins MD   +6 more
europepmc   +1 more source

Elevated Amniotic Fluid 8-Iso-Prostaglandin F<sub>2</sub>α Reveals Intrauterine Oxidative Stress in Fetuses with Congenital Heart Disease: A Prospective Case-Control Study. [PDF]

open access: yesAntioxidants (Basel)
Arráez M   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy